Prospects for New Cannabis-Based Prescription Medicines
Journal of Cannabis Therapeutics · 2001
DOI: 10.1300/j175v01n03_12 ↗Kurz gefasst
Fachartikel in der Zeitschrift Journal of Cannabis Therapeutics, 2001. Verfasst von Brian A. Whittle und 2 weiteren Autor:innen. Die Arbeit wurde bisher 40-mal zitiert (Crossref) und nennt 24 Literaturangaben.
Abstract (Originalsprache)
Cannabis is now emerging from a period of prohibition and being revisited as a potential source of treatments for conditions ill served by synthetic substances. Previous research focussed primarily on effects produced by synthetic cannabinoids such as THC, or cannabis of unknown cannabinoid content. Chemovars of cannabis characterized by high content of specific cannabinoids (primarily, but not only THC and CBD) have been developed. Clinical research using defined extracts from these chemovars is now underway in the UK. Many diseases are multifactorial; a variety of receptors need to be targeted to produce a therapeutic effect. A defined botanical may better achieve this than a single synthetic compound as the components can act synergistically. A new generation of cannabis based medicinal products takes advantage of increasing understanding of the mode of action of cannabinoids, evidence-based research on clinical uses and new technology for realization of products, in anti-diversionary presentations.
Zitieren
APA
Whittle, B. A., Guy, G. W., & Robson, P. (2001). Prospects for New Cannabis-Based Prescription Medicines. Journal of Cannabis Therapeutics. https://doi.org/10.1300/j175v01n03_12
Vancouver
Whittle BA, Guy GW, Robson P. Prospects for New Cannabis-Based Prescription Medicines. Journal of Cannabis Therapeutics. 2001. doi:10.1300/j175v01n03_12
BibTeX
@article{Whittle2001,
author = {Whittle, Brian A. and Guy, Geoffrey W. and Robson, Philip},
title = {Prospects for New Cannabis-Based Prescription Medicines},
journal = {Journal of Cannabis Therapeutics},
year = {2001},
doi = {10.1300/j175v01n03_12}
}
EUVIMED